In vivo metabolomics identifies CD38 as an emergent vulnerability in LKB1 -mutant lung cancer.
Jiehui DengDavid H PengDavid FenyoHao YuanAlfonso LopezDaniel S LevinMary MeynardieMari QuinterosMichela RanieriSoumyadip SahuSally C M LauElaine ShumVamsidhar VelchetiSalman R PunekarNatasha RekhtmanCatríona M DowlingVajira K WeerasekaraYun XueHongbin JiYik SiuDrew JonesAaron N HataTakeshi ShimamuraJohn T PoirierCharles M RudinTakamitsu HattoriShohei KoideThales PapagiannakopoulosBenjamin G NeelNabeel BardeesyKwok-Kin WongPublished in: bioRxiv : the preprint server for biology (2023)
tumor suppressor of lung adenocarcinoma patients and are associated with resistance to current treatments. Our study identified CD38 as a potential therapeutic target that is highly overexpressed in this specific subtype of cancer, associated with a shift in NAD homeostasis.